-
Radiologia 2020Breast implants are associated with well-known common complications that have been widely studied, such as rupture and capsular contraction. However, the increasingly... (Review)
Review
Breast implants are associated with well-known common complications that have been widely studied, such as rupture and capsular contraction. However, the increasingly growing number of patients with breast implants has led to the increased likelihood of coming across less common complications; these include seromas or late infection; adenopathies in the internal mammary chain; granulomas in the capsule of the implant, which in some cases can extend beyond the fibrous capsule; desmoid tumors associated with the implants; and breast implant-associated large cell anaplastic lymphoma. This article aims to review the main uncommon complications associated with breast implants and to describe and illustrate their findings in different imaging techniques. Proper management of these complications is important; this is especially true of late seroma and the diagnosis of breast implant-associated large cell anaplastic lymphoma for their repercussions.
Topics: Breast Implants; Breast Neoplasms; Female; Fibroma; Granuloma, Foreign-Body; Humans; Lymphoma, Large-Cell, Anaplastic; Postoperative Complications; Silicone Gels
PubMed: 32273126
DOI: 10.1016/j.rx.2020.01.008 -
Annals of Oncology : Official Journal... Oct 2017Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course.... (Review)
Review
An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG).
Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based treatment approach available for this disease. Therefore, in 2015 the European Desmoid Working Group published a position paper giving recommendations on the treatment of this intriguing disease. Here, we present an update of this consensus approach based on professionals' AND patients' expertise following a round table meeting bringing together sarcoma experts from the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group with patients and patient advocates from Sarcoma PAtients EuroNet. In this paper, we focus on new findings regarding the prognostic value of mutational analysis in desmoid-type fibromatosis patients and new systemic treatment options.
Topics: Fibromatosis, Aggressive; Humans; Randomized Controlled Trials as Topic
PubMed: 28961825
DOI: 10.1093/annonc/mdx323 -
Advances in Therapy Sep 2023Desmoid tumors (DT) are rare, locally aggressive, fibroblastic soft-tissue tumors that are characterized by infiltrative growth and can affect organs and adjacent... (Review)
Review
Desmoid tumors (DT) are rare, locally aggressive, fibroblastic soft-tissue tumors that are characterized by infiltrative growth and can affect organs and adjacent structures, resulting in substantial clinical burden impacting patients' health-related quality of life. Searches of PubMed, Embase, Cochrane, and key conferences were conducted in November 2021 and updated periodically through March 2023 to identify articles describing the burden of DT. Of 651 publications identified, 96 relevant ones were retained. Diagnosis of DT is challenging because of its morphologic heterogeneity and variable clinical presentation. Patients visit multiple healthcare providers, often facing delays in correct diagnosis. The low incidence of DT (estimated 3-5 cases per million person-years) limits disease awareness. Patients with DT experience a high symptom burden: up to 63% of patients experience chronic pain, which leads to sleep disturbance (73% of cases), irritability (46% of cases), and anxiety/depression (15% of cases). Frequently mentioned symptoms are pain, limited function and mobility, fatigue, muscle weakness, and swelling around the tumor. Overall, quality of life in patients with DT is lower than in healthy controls. There is no treatment approved by the US Food and Drug Administration for DT; however, treatment guidelines reference available options, such as active surveillance, surgery, systemic therapy, and locoregional therapy. Choice of active treatment may depend on tumor location, symptoms, and risk of morbidity. The substantial burden of illness of DT is related to difficulties in timely and accurate diagnosis, high symptom burden (pain and functional limitations), and decreased quality of life. There is a high unmet need for treatments that specifically target DT and improve quality of life.
Topics: Humans; Fibromatosis, Aggressive; Quality of Life; Pain
PubMed: 37436594
DOI: 10.1007/s12325-023-02592-0 -
Indian Pediatrics Nov 2021
Topics: Fibroma; Humans; Infant; Skin Diseases; Skin Neoplasms; Toes
PubMed: 34837378
DOI: No ID Found -
Journal of Clinical Pathology Jul 1968Three cases of elastofibroma are described and the literature is reviewed. It is suggested that they are non-neoplastic lesions resulting from trauma. Their staining...
Three cases of elastofibroma are described and the literature is reviewed. It is suggested that they are non-neoplastic lesions resulting from trauma. Their staining reactions and the response of the elastic type fibres to enzyme digestion suggest that these fibres are either true elastin or very closely related to it.
Topics: Aged; Back; Elastic Tissue; Elastin; Fibroma; Humans; Male; Middle Aged; Scapula
PubMed: 5697346
DOI: 10.1136/jcp.21.4.470 -
Current Treatment Options in Oncology Feb 2024Desmoid tumors are rare tumors with a tendency to infiltrate locally. The lack of a standard treatment approach makes choosing the most appropriate treatment for... (Review)
Review
Desmoid tumors are rare tumors with a tendency to infiltrate locally. The lack of a standard treatment approach makes choosing the most appropriate treatment for patients challenging. Most experts recommend watchful observation for asymptomatic patients as spontaneous regression of tumor is observed in up to 20% of patients. Upfront resection of the desmoid tumor has fallen out of favor due to high morbidity and high relapse rates associated with the tumor. Systemic therapy has evolved over several decades. Where chemotherapy, hormonal therapy, and non-steroidal anti-inflammatory drugs were used over the last several decades, tyrosine kinase inhibitors came to the forefront within the last decade. Most recently, gamma-secretase inhibitors have shown significant clinical benefit in patients with desmoid tumors, bringing forth an entirely new mechanistic approach. Several Wnt pathway inhibitors are also under development. Invasive approaches like cryoablation have also shown clinical benefit in patients with extra-abdominal desmoid tumors in recent years. The recent approval of nirogacestat has ushered in a new era of treatment for patients diagnosed with desmoid tumors. Several new molecules are expected to be approved over the coming years.
Topics: Humans; Fibromatosis, Aggressive; Retrospective Studies; Neoplasm Recurrence, Local
PubMed: 38270798
DOI: 10.1007/s11864-024-01177-5 -
Surgical Pathology Clinics Dec 2021The term giant cell-rich tumors of bone refers to a shared morphologic pattern in a group of different osseous lesions, that is, the abundance of osteoclastlike giant... (Review)
Review
The term giant cell-rich tumors of bone refers to a shared morphologic pattern in a group of different osseous lesions, that is, the abundance of osteoclastlike giant cells. Fitting with a broad spectrum of clinical presentations and biological behavior, the recent detection of characteristic molecular alterations in giant cell tumor of bone (H3-3), nonossifying fibroma (KRAS, FGFR1), giant cell granuloma of the jaws (KRAS, FGFR1, TRPV4), and aneurysmal bone cyst (USP6) have contributed significantly to the biological understanding of these morphologically related but clinically distinct lesions and their systematic classification, highlighting differences and pathogenic relationships.
Topics: Bone Cysts, Aneurysmal; Fibroma; Giant Cell Tumors; Giant Cells; Granuloma, Giant Cell; Humans
PubMed: 34742488
DOI: 10.1016/j.path.2021.06.010 -
Journal of Clinical Pathology Jul 1968Two cases of elastofibroma dorsi are reported and the light and electron microscopic features analysed. The appearances suggest that the characteristic fibres and...
Two cases of elastofibroma dorsi are reported and the light and electron microscopic features analysed. The appearances suggest that the characteristic fibres and globules that stain as for elastin arise by denaturation of collagen. The fibres differ from the elastin of arterial wall, elastotic degeneration of skin, and pseudoxanthoma elasticum. The morphology and clinical behaviour indicate that elastofibroma dorsi is a reactive fibromatosis rather than a true neoplasm.
Topics: Arteries; Back; Collagen; Elastic Tissue; Elastin; Female; Fibroma; Humans; Microscopy, Electron; Middle Aged; Pseudoxanthoma Elasticum; Scapula; Skin
PubMed: 5697345
DOI: 10.1136/jcp.21.4.463 -
The Pan African Medical Journal 2015
Topics: Adult; Female; Fibroma; Humans; Mouth Mucosa; Wounds and Injuries
PubMed: 26448815
DOI: 10.11604/pamj.2015.21.220.7498 -
Yonsei Medical Journal Dec 1991Our experience includes seven cases of ossifying fibroma. The condition also appears in the literature under diagnostic names such as congenital fibrous dysplasia,...
Our experience includes seven cases of ossifying fibroma. The condition also appears in the literature under diagnostic names such as congenital fibrous dysplasia, congenital osteitis fibrosa, congenital fibrous defect of the tibia, and osteofibrous dysplasia of the tibia and fibula. The lesions develop in childhood and are located in the diaphysis of the tibia, or fibula. Of seven patients, we performed wide excision with free vascularized fibular graft in five cases, wide resection of the distal one-third of the fibula in one case, and curettage and bone graft in one case. Two of the patients who had wide excision with free vascularized fibular graft had recurrence. One case of recurrence occurred where incomplete wide excision with free-vascularized fibular graft was performed because the lesion was too close to the distal epiphysis of the tibia. One of the patients who had curettage and bone graft also had recurrence. It was concluded that children who have an ossifying fibroma requiring surgery can safely be treated with wide excision with or without free-vascularized fibular graft.
Topics: Adolescent; Bone Neoplasms; Child; Female; Fibroma; Humans; Male; Osteoma; Tibia
PubMed: 1812656
DOI: 10.3349/ymj.1991.32.4.347